Express Scripts Defends 340B Claims ID Requirement

Express Scripts told 340B covered entities in recent letters that it has granted "numerous" extensions of time for pharmacies to comply with its new 340B claims identification process.
Pharmacy benefits manager Express Scripts (ESI) told a hospital group and an HIV/AIDS clinic in recent days that it has “already granted numerous pharmacies extensions” to its controversial new 340B claims identification requirement that went into effect March 1.
Read More »

Panel Lauds Women’s Role in Creating and Leading 340B

Participants in last week's Notable Women of 340B webinar included, clockwise from top left, Peggy Tighe, Colleen Meiman, Colleen DiClaudio, Marilyn Hayes, and Lorrie Carr.
Women have played a key role in the 340B program since its inception nearly 30 years ago. Their historic and ongoing involvement was observed and celebrated in “Notable Women of 340B,” a webinar broadcast by Community Voices for 340B (CV-340B)
Read More »

340B Groups Ask Express Scripts to Drop Claims Submission and ID Requirement

The 340B Coalition told Express Scripts that covered entities cannot comply with its new 340B claims submission and identification requirement absent "a massive investment of financial and human resources." | Shutterstock
Groups representing 340B health care providers have asked pharmacy benefit manager Express Scripts (ESI) to stop making 340B providers and their contract pharmacies retrospectively submit and flag 340B claims in a way that has never been done before, and that
Read More »

Survey: Pharma’s 340B Contract Pharmacy Actions are Putting the Squeeze on Hospitals

Nearly all (97 percent) of all 340B hospitals in a recent survey said they are impacted by drug manufacturers' curbs on contract pharmacy use. | Shutterstock
340B hospitals are under significant pressure due to drug manufacturers ending 340B discounts on drugs dispensed by contract pharmacies, hospital advocacy group 340B Health says in its latest annual member survey.

Please Login or Become a

Read More »

Health Care Reporter Foresees Federal Action on Drug Pricing, But Not Immediately

Politico Pro reporter Sarah Owermohle told 340B Coalition winter conference attendees she thinks President Biden will turn to drug pricing after dealing first with the COVID-19 pandemic and bolstering the Affordable Care Act.
The U.S. Senate Finance Committee’s new Democratic chair is considering bringing back a bipartisan bill from the last session of Congress that would require drug manufacturers to pay the federal government rebates on Medicare Part B and Part D drugs
Read More »

Biden Will Turn to Drug Pricing Once COVID-19 Ebbs, Shalala Predicts

Former HHS Secretary Donna Shalala (right) holds her rescue dog, Fauci, at the end of her talk yesterday during the 340B Coalition winter conference.
President Biden will likely turn to lowering drug prices once the COVID-19 pandemic stops demanding so much of his attention, Donna Shalala, U.S. Health and Human Services (HHS) Secretary during both of President Clinton’s terms in office, predicted in a
Read More »

AHA Asks CMS to Withdraw Trump’s Most Favored Nation Drug Pricing Rule

During an October 2018 event at HHS, former President Trump promised to end "global freeloading" that caused Americans to pay higher drug prices. | Source: C-SPAN
The American Hospital Association (AHA) asked the Biden administration this week to immediately withdraw the Trump administration’s “most favored nation” (MFN) drug pricing interim final rule, in part, because of the damage it will do to 340B hospitals and “critical
Read More »

340B Stakeholders Reconsider Campaign Contributions in Wake of Capitol Riot

Businesses and groups involved in 340B are reconsidering their political donations following a pro-Trump mob's assault on the U.S. Capitol. | Source: Shutterstock
National health care organizations and businesses with major stakes in the 340B program have suspended political contributions following a pro-Trump mob’s Jan. 6 violent attack on Congress to stop it from counting and certifying the Electoral College’s votes for president.
Read More »

Providers Are Pleased, PhRMA Isn’t, With Becerra and State AGs’ 340B Letter to Azar

Health care providers are applauding a bipartisan group of 29 state attorneys general (including the District of Columbia’s) for their letter yesterday to HHS Secretary Alex Azar urging him “to address drug manufacturers’ unlawful refusal to provide critical drug discounts
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report